ProQR Therapeutics N.V. (NASDAQ:PRQR) has received an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $16.38.

A number of analysts have recently issued reports on the company. Zacks Investment Research raised ProQR Therapeutics N.V. from a “sell” rating to a “hold” rating in a research report on Wednesday, May 3rd. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of ProQR Therapeutics N.V. in a report on Tuesday, June 20th.

TRADEMARK VIOLATION WARNING: “ProQR Therapeutics N.V. (PRQR) Given Average Recommendation of “Buy” by Analysts” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at

An institutional investor recently raised its position in ProQR Therapeutics N.V. stock. Sphera Funds Management LTD. boosted its position in ProQR Therapeutics N.V. (NASDAQ:PRQR) by 65.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 330,000 shares of the biopharmaceutical company’s stock after buying an additional 130,000 shares during the period. Sphera Funds Management LTD. owned approximately 1.41% of ProQR Therapeutics N.V. worth $1,650,000 as of its most recent SEC filing. Institutional investors and hedge funds own 38.81% of the company’s stock.

Shares of ProQR Therapeutics N.V. (PRQR) opened at 4.90 on Monday. The stock’s market cap is $116.94 million. The firm’s 50-day moving average price is $5.02 and its 200 day moving average price is $4.63. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70.

ProQR Therapeutics N.V. (NASDAQ:PRQR) last released its quarterly earnings data on Wednesday, May 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.02. Equities research analysts expect that ProQR Therapeutics N.V. will post ($2.13) EPS for the current fiscal year.

ProQR Therapeutics N.V. Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with's FREE daily email newsletter.